Tissue Regenix Proposes Acquisition of CellRight Technologies

Tissue Regenix announced its proposed acquisition of CellRight Technologies for US $30MM. Combined, the companies would offer products for bone and soft tissue regeneration based on CellRight's human-derived bone grafts and Tissue Regenix’s dCELL® decellularization platform.

CellRight gains access to a new geographies for its...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

JV

Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.



Contact Us

0